The beta-globin gene cluster has shown high polymorphic diversity organized in 5' and 3' haplotypes (Hps). beta(S)-Chromosomes are in linkage disequilibrium with the 5' Hps Bantu, Benin, Senegal, Cameroon, and Arab-Indian. In Mexican mestizos with African west coast origins, we observed the following 5' Hps in beta(S)-chromosomes: Bantu, 78.8%; Benin, 18.2%; and atypical Hp 9, 3.0%. With the purpose of establishing the 3' Hps, we analyzed 35 polymorphic sites--6 by RFLP analysis and 29 by DNA sequencing--in 33 unrelated beta(S)-chromosomes. The polymorphic sites were structured according to Harding et al. [R.M. Harding, S.M. Fullerton, R.C. Griffiths, J.B. Clegg, Archaic African and Asian lineages in the genetic ancestry of modern humans, Am. J. Hum. Genet. 60 (1997) 772-789] and Lapoumeroulie et al. [C. Lapoumeroulie, O. Dunda, R. Ducrocq, G. Trabuchet, M. Mony-Lobe, J.M. Bodo, P. Carnevale, D. Labie, J. Elion, R. Krishnamoorthy, A novel sickle cell mutation of yet another origin in Africa: the Cameroon type, Hum. Genet. 89 (1992) 333-337]. All Bantu beta(S)-chromosomes showed the 12A1 3' Hp with (AT)6T9 repeats (84.9%), a novel 3' Hp. The Benin Hp was 2B2, with (AT)8T4 (12.1%), and the atypical Hp 9 4B1, (AT)8T5 (3.0%). Because of the high linkage disequilibrium observed for the Bantu and 12A1 Hps, we expect that, if there is a single origin of the Bantu beta(S) mutation, all must show the 12A1 polymorphic DNA sequence in the 3' Hp. A correlation between the 5' and 3' Hps could be observed with the other beta(S) mutations. The atypical Hp 9 was also atypical at the 3' Hp, with the same repeats as observed with the Cameroon beta(S) mutation; however, it differed in one position from the typical Lapoumeroulie Cameroon Hp, indicating that these beta(S)-chromosomes arose by different genetic mechanisms or by a novel beta(S) mutation. We stress the importance of the study of DNA polymorphisms at 3' Hp to allow understanding of the genetic diversity of beta(S)-chromosomes, as well as their implications in beta(S) gene expression and the possible effects on the clinical phenotype.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bcmd.2004.08.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the potential of TGFβ as a diagnostic marker and therapeutic target against cancer.
Biochem Pharmacol
January 2025
Departments of Medical Oncology & Therapeutics Research, USA. Electronic address:
Transforming Growth Factor-beta (TGF-β) is a multifunctional cytokine that exerts its biological effects through a complex process of activation and signaling. Initially synthesized in an inactive form bound to latency-associated peptide (LAP), TGF-β requires release from the extracellular matrix via proteolytic cleavage or integrin-mediated activation to engage with its receptors. Once active, TGF-β binds to type II receptor (TβRII), which then phosphorylates and activates type I receptor (TβRI), triggering downstream signaling cascades, including both Smad-dependent and non-Smad pathways.
View Article and Find Full Text PDFSickle cell anemia (SCA) results from a mutation in the -globin gene, leading to the production of mutant hemoglobin, known as hemoglobin S (HbS). Despite being a genetic disorder, the phenotype of SCA can be influenced by the level of fetal hemoglobin (HbF), which is associated with beta S-globin haplotypes. In this study, we conducted newborn screening (NBS) using samples collected from umbilical cord blood in two hospitals on Santiago Island, Cape Verde.
View Article and Find Full Text PDFA multiplexed, allele-specific recombinase polymerase amplification assay with lateral flow readout for sickle cell disease detection.
Lab Chip
August 2024
Department of Bioengineering, Rice University, Houston, TX, USA.
Isothermal nucleic acid amplification tests have the potential to improve disease diagnosis at the point of care, but it remains challenging to develop multiplexed tests that can detect ≥3 targets or to detect point mutations that may cause disease. These capabilities are critical to enabling informed clinical decision-making for many applications, such as sickle cell disease (SCD). To address this, we describe the development of a multiplexed allele-specific recombinase polymerase amplification (RPA) assay with lateral flow readout.
View Article and Find Full Text PDFClinical, laboratory, and molecular characteristics of a cohort of children with hemoglobinopathy S/beta-thalassemia.
Hematol Transfus Cell Ther
December 2023
Faculdade de Medicina/Núcleo de Ações e Pesquisa em Apoio Diagnóstico (NUPAD), UFMG, Belo Horizonte, MG, Brazil. Electronic address:
Introduction: Hemoglobinopathy Sβ-thalassemia (HbSβ-thal) has a wide range of clinical and laboratory severity. There is limited information on the natural history of HbSβ-thal and its modulating factors. We described the molecular, hematological, and clinical characteristics of a cohort of children with HbSβ-thal and estimated its incidence in Minas Gerais, Brazil.
View Article and Find Full Text PDFAn α-chain modification rivals the effect of fetal hemoglobin in retarding the rate of sickle cell fiber formation.
Sci Rep
December 2023
Department of Physics, Drexel University, Philadelphia, PA, 19104, USA.
Adults with sickle cell disease bear a mutation in the β-globin gene, leading to the expression of sickle hemoglobin (HbS; αβ). Adults also possess the gene for γ-globin, which is a component of fetal hemoglobin (HbF, αγ); however, γ-chain expression normally ceases after birth. As HbF does not form the fibers that cause the disease, pharmacological and gene-modifying interventions have attempted to either reactivate expression of the γ chain or introduce a gene encoding a modified β chain having γ-like character.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!